CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda

Jeffrey K. Wickliffe, Sherif Abdel-Rahman, Chul Lee, Csilla Kormos-Hallberg, Gagan Sood, Catherine M. Rondelli, James J. Grady, Robert J. Desnick, Karl Anderson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Porphyria cutanea tarda (PCT) is a cutaneous porphyria with sporadic (type 1) and familial (type 2) subtypes, both resulting from decreased hepatic uroporphyrinogen decarboxylase (UROD) activity. Environmental and genetic factors are involved in the development of PCT, and genetic variants in the cytochrome P450 (CYP) genes, CYP1A1 and CYP1A2, have been implicated. We investigated the association between PCT and variants in CYP1A1, CYP1A2 and CYP2E1, and the glutathione-S-ransferase (GST) genes, GSTM1 and GSTT1. PCT diagnosis was based on urinary or plasma porphyrin profiles. Patients were classified as type 1 or 2 PCT based on UROD mutation analysis. The CYP1A21F promoter A allele frequency was significantly higher (P < 0.022) and the A/A genotype frequency marginally higher in PCT patients overall (P < 0.057), with the A/A genotype significantly more common in type 1 PCT (P < 0.043). The presence of the wild-type GSTM1 allele also was associated significantly with PCT (P < 0.019). Neither hemochromatosis (HFE) mutations, tobacco smoking, hepatitis C and HIV infection, ethanol consumption, nor estrogen use were associated with these allelic variants. Age at onset was significantly lower in type 2 PCT patients (P < 0.001), as observed previously. Thus, positive associations between PCT and the CYP1A21F promoter A allele and A/A genotype and the wild-type GSTM1 allele indicates that these functional hepatic biotransformation enzymes are risk factors for the development of this disease.

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalMolecular Medicine
Volume17
Issue number3-4
DOIs
StatePublished - Mar 2011

Fingerprint

Porphyria Cutanea Tarda
Cytochrome P-450 CYP1A2
Alleles
Uroporphyrinogen Decarboxylase
Cytochrome P-450 CYP1A1
Genotype
Porphyrias
Cytochrome P-450 CYP2E1
Mutation
Hemochromatosis
Liver
Porphyrins
Hepatitis C
Biotransformation
Age of Onset
Gene Frequency
Cytochrome P-450 Enzyme System
Genes
HIV Infections
Glutathione

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Medicine(all)

Cite this

CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. / Wickliffe, Jeffrey K.; Abdel-Rahman, Sherif; Lee, Chul; Kormos-Hallberg, Csilla; Sood, Gagan; Rondelli, Catherine M.; Grady, James J.; Desnick, Robert J.; Anderson, Karl.

In: Molecular Medicine, Vol. 17, No. 3-4, 03.2011, p. 241-247.

Research output: Contribution to journalArticle

Wickliffe, JK, Abdel-Rahman, S, Lee, C, Kormos-Hallberg, C, Sood, G, Rondelli, CM, Grady, JJ, Desnick, RJ & Anderson, K 2011, 'CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda', Molecular Medicine, vol. 17, no. 3-4, pp. 241-247. https://doi.org/10.2119/molmed.2010.00130
Wickliffe, Jeffrey K. ; Abdel-Rahman, Sherif ; Lee, Chul ; Kormos-Hallberg, Csilla ; Sood, Gagan ; Rondelli, Catherine M. ; Grady, James J. ; Desnick, Robert J. ; Anderson, Karl. / CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. In: Molecular Medicine. 2011 ; Vol. 17, No. 3-4. pp. 241-247.
@article{b5b818838f294e9e98cb953900c3df04,
title = "CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda",
abstract = "Porphyria cutanea tarda (PCT) is a cutaneous porphyria with sporadic (type 1) and familial (type 2) subtypes, both resulting from decreased hepatic uroporphyrinogen decarboxylase (UROD) activity. Environmental and genetic factors are involved in the development of PCT, and genetic variants in the cytochrome P450 (CYP) genes, CYP1A1 and CYP1A2, have been implicated. We investigated the association between PCT and variants in CYP1A1, CYP1A2 and CYP2E1, and the glutathione-S-ransferase (GST) genes, GSTM1 and GSTT1. PCT diagnosis was based on urinary or plasma porphyrin profiles. Patients were classified as type 1 or 2 PCT based on UROD mutation analysis. The CYP1A21F promoter A allele frequency was significantly higher (P < 0.022) and the A/A genotype frequency marginally higher in PCT patients overall (P < 0.057), with the A/A genotype significantly more common in type 1 PCT (P < 0.043). The presence of the wild-type GSTM1 allele also was associated significantly with PCT (P < 0.019). Neither hemochromatosis (HFE) mutations, tobacco smoking, hepatitis C and HIV infection, ethanol consumption, nor estrogen use were associated with these allelic variants. Age at onset was significantly lower in type 2 PCT patients (P < 0.001), as observed previously. Thus, positive associations between PCT and the CYP1A21F promoter A allele and A/A genotype and the wild-type GSTM1 allele indicates that these functional hepatic biotransformation enzymes are risk factors for the development of this disease.",
author = "Wickliffe, {Jeffrey K.} and Sherif Abdel-Rahman and Chul Lee and Csilla Kormos-Hallberg and Gagan Sood and Rondelli, {Catherine M.} and Grady, {James J.} and Desnick, {Robert J.} and Karl Anderson",
year = "2011",
month = "3",
doi = "10.2119/molmed.2010.00130",
language = "English (US)",
volume = "17",
pages = "241--247",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",
number = "3-4",

}

TY - JOUR

T1 - CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda

AU - Wickliffe, Jeffrey K.

AU - Abdel-Rahman, Sherif

AU - Lee, Chul

AU - Kormos-Hallberg, Csilla

AU - Sood, Gagan

AU - Rondelli, Catherine M.

AU - Grady, James J.

AU - Desnick, Robert J.

AU - Anderson, Karl

PY - 2011/3

Y1 - 2011/3

N2 - Porphyria cutanea tarda (PCT) is a cutaneous porphyria with sporadic (type 1) and familial (type 2) subtypes, both resulting from decreased hepatic uroporphyrinogen decarboxylase (UROD) activity. Environmental and genetic factors are involved in the development of PCT, and genetic variants in the cytochrome P450 (CYP) genes, CYP1A1 and CYP1A2, have been implicated. We investigated the association between PCT and variants in CYP1A1, CYP1A2 and CYP2E1, and the glutathione-S-ransferase (GST) genes, GSTM1 and GSTT1. PCT diagnosis was based on urinary or plasma porphyrin profiles. Patients were classified as type 1 or 2 PCT based on UROD mutation analysis. The CYP1A21F promoter A allele frequency was significantly higher (P < 0.022) and the A/A genotype frequency marginally higher in PCT patients overall (P < 0.057), with the A/A genotype significantly more common in type 1 PCT (P < 0.043). The presence of the wild-type GSTM1 allele also was associated significantly with PCT (P < 0.019). Neither hemochromatosis (HFE) mutations, tobacco smoking, hepatitis C and HIV infection, ethanol consumption, nor estrogen use were associated with these allelic variants. Age at onset was significantly lower in type 2 PCT patients (P < 0.001), as observed previously. Thus, positive associations between PCT and the CYP1A21F promoter A allele and A/A genotype and the wild-type GSTM1 allele indicates that these functional hepatic biotransformation enzymes are risk factors for the development of this disease.

AB - Porphyria cutanea tarda (PCT) is a cutaneous porphyria with sporadic (type 1) and familial (type 2) subtypes, both resulting from decreased hepatic uroporphyrinogen decarboxylase (UROD) activity. Environmental and genetic factors are involved in the development of PCT, and genetic variants in the cytochrome P450 (CYP) genes, CYP1A1 and CYP1A2, have been implicated. We investigated the association between PCT and variants in CYP1A1, CYP1A2 and CYP2E1, and the glutathione-S-ransferase (GST) genes, GSTM1 and GSTT1. PCT diagnosis was based on urinary or plasma porphyrin profiles. Patients were classified as type 1 or 2 PCT based on UROD mutation analysis. The CYP1A21F promoter A allele frequency was significantly higher (P < 0.022) and the A/A genotype frequency marginally higher in PCT patients overall (P < 0.057), with the A/A genotype significantly more common in type 1 PCT (P < 0.043). The presence of the wild-type GSTM1 allele also was associated significantly with PCT (P < 0.019). Neither hemochromatosis (HFE) mutations, tobacco smoking, hepatitis C and HIV infection, ethanol consumption, nor estrogen use were associated with these allelic variants. Age at onset was significantly lower in type 2 PCT patients (P < 0.001), as observed previously. Thus, positive associations between PCT and the CYP1A21F promoter A allele and A/A genotype and the wild-type GSTM1 allele indicates that these functional hepatic biotransformation enzymes are risk factors for the development of this disease.

UR - http://www.scopus.com/inward/record.url?scp=79952919700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952919700&partnerID=8YFLogxK

U2 - 10.2119/molmed.2010.00130

DO - 10.2119/molmed.2010.00130

M3 - Article

C2 - 20957336

AN - SCOPUS:79952919700

VL - 17

SP - 241

EP - 247

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

IS - 3-4

ER -